Movement Alert｜CANSINOBIO Rises 5.08% in Regular Trading, Interim Earnings Turnaround and Equity Incentive Plan Continue to Boost Sentiment

Market Focus09-21 10:04

On September 21, CANSINOBIO rose 5.08% in regular trading, trading at HK$27.78/share, with turnover of HK$62.90 million, extending gains following a series of positive developments in recent sessions.

On the news front, the company recently disclosed interim results showing first-half revenue of approximately RMB 5.47 billion, up 46.1% year-over-year, while operating profit reached RMB 27.54 million, marking a turnaround from losses. Adjusted net loss narrowed sharply to just RMB 721,000 from RMB 13.49 million a year earlier. Overseas revenue surged 4,724.19% year-over-year to RMB 152 million, reflecting accelerating internationalization across vaccine sales, intermediate supply, and technology transfer. Additionally, on September 16, the company granted 287,400 restricted A-shares to 19 employees at RMB 41.20 per share under its equity incentive plan, signaling management confidence. CLSA maintained an Outperform rating with a HK$49.6 target price. Within the Biotechnology sector, AKESO rose 8.78%, INNOVENT BIO gained 6.63%, and SKB BIO added 6.15%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161868110?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161868110","market":"us","top_or_hot":-1,"title":"Movement Alert｜CANSINOBIO Rises 5.08% in Regular Trading, Interim Earnings Turnaround and Equity Incentive Plan Continue to Boost Sentiment","media":"Market Focus","content":"<p><p>On September 21, CANSINOBIO rose 5.08% in regular trading, trading at HK$27.78/share, with turnover of HK$62.90 million, extending gains following a series of positive developments in recent sessions.</p><p>On the news front, the company recently disclosed interim results showing first-half revenue of approximately RMB 5.47 billion, up 46.1% year-over-year, while operating profit reached RMB 27.54 million, marking a turnaround from losses. Adjusted net loss narrowed sharply to just RMB 721,000 from RMB 13.49 million a year earlier. Overseas revenue surged 4,724.19% year-over-year to RMB 152 million, reflecting accelerating internationalization across vaccine sales, intermediate supply, and technology transfer. Additionally, on September 16, the company granted 287,400 restricted A-shares to 19 employees at RMB 41.20 per share under its equity incentive plan, signaling management confidence. CLSA maintained an Outperform rating with a HK$49.6 target price. Within the Biotechnology sector, AKESO rose 8.78%, INNOVENT BIO gained 6.63%, and SKB BIO added 6.15%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CANSINOBIO Rises 5.08% in Regular Trading, Interim Earnings Turnaround and Equity Incentive Plan Continue to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CANSINOBIO Rises 5.08% in Regular Trading, Interim Earnings Turnaround and Equity Incentive Plan Continue to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-21 10:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 21, CANSINOBIO rose 5.08% in regular trading, trading at HK$27.78/share, with turnover of HK$62.90 million, extending gains following a series of positive developments in recent sessions.</p><p>On the news front, the company recently disclosed interim results showing first-half revenue of approximately RMB 5.47 billion, up 46.1% year-over-year, while operating profit reached RMB 27.54 million, marking a turnaround from losses. Adjusted net loss narrowed sharply to just RMB 721,000 from RMB 13.49 million a year earlier. Overseas revenue surged 4,724.19% year-over-year to RMB 152 million, reflecting accelerating internationalization across vaccine sales, intermediate supply, and technology transfer. Additionally, on September 16, the company granted 287,400 restricted A-shares to 19 employees at RMB 41.20 per share under its equity incentive plan, signaling management confidence. CLSA maintained an Outperform rating with a HK$49.6 target price. Within the Biotechnology sector, AKESO rose 8.78%, INNOVENT BIO gained 6.63%, and SKB BIO added 6.15%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1161868110","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161868110","pubTimestamp":1789956263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 21, CANSINOBIO rose 5.08% in regular trading, trading at HK$27.78/share, with turnover of HK$62.90 million, extending gains following a series of positive developments in recent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"走势提醒|康希诺生物常规交易上涨5.08%，中期盈利扭亏为盈和股权激励计划继续提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"On September 21, CANSINOBIO rose 5.08% in regular trading, trading at HK$27.78/share, with turnover of HK$62.90 million, extending gains following a series of positive developments in recent sessions.On the news front, the company recently disclosed interim results showing first-half revenue of approximately RMB 5.47 billion, up 46.1% year-over-year, while operating profit reached RMB 27.54 million, marking a turnaround from losses. Adjusted net loss narrowed sharply to just RMB 721,000 from RMB 13.49 million a year earlier. Overseas revenue surged 4,724.19% year-over-year to RMB 152 million, reflecting accelerating internationalization across vaccine sales, intermediate supply, and technology transfer. Additionally, on September 16, the company granted 287,400 restricted A-shares to 19 employees at RMB 41.20 per share under its equity incentive plan, signaling management confidence. CLSA maintained an Outperform rating with a HK$49.6 target price. Within the Biotechnology sector, AKESO rose 8.78%, INNOVENT BIO gained 6.63%, and SKB BIO added 6.15%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161868110","isCrawlerRequest":true}